Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
114 hedge funds and large institutions have $728M invested in Endocyte, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 18 increasing their positions, 24 reducing their positions, and 28 closing their positions.
93% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 28
71% more capital invested
Capital invested by funds: $426M → $728M (+$302M)
28% more funds holding
Funds holding: 89 → 114 (+25)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
25% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 24
28% less call options, than puts
Call options by funds: $4.41M | Put options by funds: $6.12M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$41.5M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$21M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$18.3M |
| 4 |
State Street
Boston,
Massachusetts
|
+$18M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$11.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
-$20.2M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$13.6M |
| 3 |
D.E. Shaw & Co
New York
|
-$11.1M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.9M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.93M |
ECYT Hedge Fund Activity: Q2 2018 in Review
114 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q2 2018, worth a combined $728M — up 71% from $426M a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new ECYT positions and 28 closed out — a net gain of 26 holders — while 18 added to existing stakes and 24 trimmed.
The largest buyer was BlackRock, adding an estimated $41.5M. The largest seller was Ghost Tree Capital, cutting an estimated $20.2M.
- 114 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q2 2018, up from 89 in Q1 2018.
- Funds reported $728M of Endocyte, Inc. Common Stock stock for Q2 2018, up 71% quarter-over-quarter.
- 54 funds opened new Endocyte, Inc. Common Stock positions in Q2 2018 and 28 closed out, a net change of +26 holders.
- The largest Endocyte, Inc. Common Stock buyer in Q2 2018 was BlackRock, an estimated $41.5M added.
- The largest Endocyte, Inc. Common Stock seller in Q2 2018 was Ghost Tree Capital, an estimated $20.2M sold.
Based on aggregated 13F filings for Q2 2018.